Medscape Conference Coverage, based on selected sessions at the:
Transcatheter Cardiovascular Therapeutics 2004
September 27, 2004 - October 1, 2004, Washington, DC

This activity is not sanctioned by, nor a part of, the Transcatheter Cardiovascular Therapeutics 2004 Meeting.


Also On This Page:Conference News
Session Coverage
AIMI: AngioJet Rheolytic Thrombectomy In Patients Undergoing Primary Angioplasty for Acute Myocardial Infarction
Use of rheolytic thrombectomy followed by definitive PCI in acute myocardial infarction patients failed to show a benefit in infarct size and other secondary endpoints compared with primary PCI alone.
AGENT 3: Angiogenic Gene Therapy 3 Trial -- Intracoronary Administration of Ad.FGF-4 in Patients With No Revascularization Options
Do the results of AGENT 3 close the book on the promise of intracoronary infusion of the human angiogenic FGF-4 gene in patients with stable angina and no other revascularization options?
Drug-Eluting Stents
ARTS-II: A Multicenter Prospective Registry of Multivessel Stenting With the Polymer-Based Sirolimus-Eluting Stent - Long-term Results
In ARTS I, the rate of repeat revascularization was higher in the bare metal stent group than in the CABG group; could the use of a drug-eluting stent make the difference?
DIABETES: Diabetes and Sirolimus-Eluting Stent Trial
Do the results of this study suggest that the sirolimus-eluting stent will be the frontline therapy for diabetic patients with de novo coronary stenoses? Are the results only applicable to non-insulin-dependent diabetics?
TAXUS II: Two-Year Results With Angiographic and IVUS Follow-up -- Slow- and Moderate-Release Paclitaxel-Eluting Stent
Favorable safety and efficacy profile observed at 6 months and 1 year persisted at 2-year follow-up, demonstrating that the use of the Taxus stent prevents, rather than delays, in-stent restenosis.
TAXUS VI: Two-Year Results From the Pivotal Prospective Randomized Trial of the Slow-Release Polymer-Based Paclitaxel-Eluting Stent
More long-term results support the use of the Taxus paclitaxel-eluting stent for an array of patient populations.
SPIRIT FIRST: Everolimus-Eluting Durable Polymer on the ML VISION Platform -- Baseline and 6-Month Follow-up
Use of the everolimus-eluting stent significantly reduced late loss and binary restenosis; MACE rate at 6 months also impressive.
Management of Saphenous Vein Graft Disease
CAPTIVE: CardioShield Application Protects During Transluminal Intervention of Vein Grafts by Reducing Emboli
Use of the CardioShield distal protection device in SVG lesions failed to show superiority to no protection and failed to show noninferiority to the GuideWire device with respect to 30-day MACE.
PRIDE: A Prospective Randomized Controlled Trial of Distal Protection With the Kensey-Nash TriActiv System
Is the use of the TriActiv distal protection system to treat diseased saphenous vein graft disease noninferior to current standards of care for the prevention of 30-day MACE?
Symbiot III: A Prospective Randomized Trial of a PTFE Self-Expanding Stent Graft During SVG Intervention -- Late Results
A good concept from a theoretical standpoint, but does the use of an ePTFE-coated nitinol stent for the treatment of SVG disease reduce the incidence of restenosis compared with a bare metal stent?
Carotid Stenting
CABERNET: Carotid Artery Revascularization Using the Boston Scientific FilterWire EX/EZ and the EndoTex NexStent
Preliminary safety data of carotid artery stent and distal protection device system appears safe and compares well with other carotid artery stenting trials.
MAVErIC I & II Trials: Evaluation of the Medtronic AVE Self-Expanding Carotid Stent System in the Treatment of Carotid Stenosis
Patients at high risk for carotid endarterectomy now have a viable alternative: coronary artery stenting. More data suggest the procedure, which uses distal protection, is associated with a low rate of major adverse events.
Conference News
Interventional Cardiologists Set Their Sights on Heart Failure Treatment 10/11/04
[Medscape CRM News]
Will the future of interventional cardiology include "interventional heart failure"? Will (Can) interventional cardiologists perform CRT and ICD implants?
Stem Cell Therapy May Be the Future of MI Treatment 10/4/04
[Medscape Medical News]
Treatment with bone marrow stem cells improved left ventricular function and enhanced blood flow to the heart in patients who had experienced myocardial infarction.
Novel Remote Control PCI System May Be More Effective, Safer 10/4/04
[Medscape Medical News]
A remote control percutaneous coronary intervention system provides greater control and increased precision in an x-ray free environment; the system may obviate the need for heavy protective gear and may reduce operator back injury.

 
Legal Disclaimer
The materials presented here were prepared by independent authors under the editorial supervision of Medscape and do not represent a publication of the Transcatheter Cardiovascular Therapeutics 2004 Meeting. These materials and the related activity are not sanctioned by the Transcatheter Cardiovascular Therapeutics 2004 Meeting, and do not constitute an official part of that conference.
The materials presented here do not reflect the views of Medscape. These materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. All readers or continuing education participants should verify all information and data before treating patients or employing any therapies described in this educational activity.
Copyright © 2004 Medscape.

 
WebMD
All material on this website is protected by copyright, Copyright © 1994-2008 by Medscape. This website also contains material copyrighted by 3rd parties.